News
Lynozyfic’s global sales are projected to reach $707 million by 2031.
NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback